Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,759 INR | +7.89% | +11.11% | +32.98% |
Jul. 04 | INDIA STOCKS-IT leads Indian shares to record highs | RE |
Jun. 28 | India plans incentives for diabetes, obesity drug makers in 2026, government official says | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 40.69 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 4.17 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+32.98% | 8.91B | - | ||
+54.07% | 809B | C+ | ||
+38.95% | 621B | B | ||
-7.05% | 351B | C+ | ||
+15.44% | 319B | B- | ||
+5.72% | 289B | C+ | ||
+14.21% | 238B | B+ | ||
-0.45% | 221B | A+ | ||
+14.58% | 218B | B- | ||
+7.42% | 166B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 500257 Stock
- LUPIN Stock
- Ratings Lupin Limited